MaxCyte Stock

MaxCyte ROE 2024

MaxCyte ROE

-0.16

Ticker

MXCT

ISIN

US57777K1060

WKN

A2AGVE

In 2024, MaxCyte's return on equity (ROE) was -0.16, a 76.03% increase from the -0.09 ROE in the previous year.

MaxCyte Aktienanalyse

What does MaxCyte do?

MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding MaxCyte's Return on Equity (ROE)

MaxCyte's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing MaxCyte's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

MaxCyte's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in MaxCyte’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about MaxCyte stock

What is the ROE (Return on Equity) of MaxCyte this year?

The ROE of MaxCyte this year is -0.16 undefined.

How has the Return on Equity (ROE) of MaxCyte developed compared to the previous year?

The ROE of MaxCyte has increased by 76.03% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of MaxCyte?

A high ROE indicates that MaxCyte generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of MaxCyte?

A low ROE can indicate that MaxCyte is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of MaxCyte affect the company?

A change in ROE (Return on Equity) of MaxCyte can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of MaxCyte?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of MaxCyte?

Some factors that can influence MaxCyte's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does MaxCyte pay?

Over the past 12 months, MaxCyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MaxCyte is expected to pay a dividend of 0 USD.

What is the dividend yield of MaxCyte?

The current dividend yield of MaxCyte is .

When does MaxCyte pay dividends?

MaxCyte pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of MaxCyte?

MaxCyte paid dividends every year for the past 0 years.

What is the dividend of MaxCyte?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is MaxCyte located?

MaxCyte is assigned to the 'Health' sector.

Wann musste ich die Aktien von MaxCyte kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of MaxCyte from 12/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/6/2024.

When did MaxCyte pay the last dividend?

The last dividend was paid out on 12/6/2024.

What was the dividend of MaxCyte in the year 2023?

In the year 2023, MaxCyte distributed 0 USD as dividends.

In which currency does MaxCyte pay out the dividend?

The dividends of MaxCyte are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von MaxCyte

Our stock analysis for MaxCyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MaxCyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.